Application of Glibenclamide in Preparation of Drugs for Protecting Radiation-induced Lung Injury

A radiation-induced lung injury and drug technology, applied in the field of biomedicine, can solve problems such as the preventive effect of glibenclamide that has not been reported in the literature, and achieve the effects of reducing toxic damage, small toxic and side effects, and clear pharmacological effects

Inactive Publication Date: 2019-10-29
SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] At present, there is no literature reporting the prevention and treatment effect of glibenclamide in radiation-induced lung injury

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Glibenclamide in Preparation of Drugs for Protecting Radiation-induced Lung Injury
  • Application of Glibenclamide in Preparation of Drugs for Protecting Radiation-induced Lung Injury
  • Application of Glibenclamide in Preparation of Drugs for Protecting Radiation-induced Lung Injury

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] Example 1: Glibenclamide can reduce lung injury and pulmonary hemorrhage in mice after irradiation

[0029] 1. Experimental method

[0030] C57 / BL6, 7-week-old male mice were selected for the experiment, and the mice were divided into three groups: unirradiated group, glibenclamide group and control group. The non-irradiated group was neither injected nor irradiated. The glibenclamide group was intraperitoneally injected with glibenclamide (10 mg / kg) 1 hour before irradiation, and the inglibenclamide was treated with dimethyl sulfoxide (DMSO). ) dissolved, so the mice in the control group were intraperitoneally injected with the same dose of DMSO solution.

[0031] The mice in the glibenclamide group and the control group were irradiated by a single dose of local chest irradiation, the dose was 30Gy, the dose rate was 1Gy / min, and the irradiation source was 60Coγ-rays. During irradiation, the lungs are exposed to the irradiation field, and the rest is covered with lea...

Embodiment 2

[0037] Example 2: Glibenclamide reduces apoptosis of vascular endothelial cell line HUVEC after irradiation

[0038] 1. Experimental method:

[0039] In order to verify the effect of glibenclamide on cell apoptosis after irradiation, apoptosis detection was performed on the vascular endothelial cell line HUVEC after irradiation.

[0040] Apoptosis was detected by AnnexinV / PI double-staining (purchased from Invitrogen) flow cytometry method, the principle of which is: apoptosis is a process of programmed initiation, which can be divided into two processes: early apoptosis and late apoptosis. During early apoptosis, phosphatidylserine (PS) can change from the original state inside the cell phospholipid membrane to outward. At this time, Annexin V can combine with the everted PS as a detection mark of early apoptosis. In the late stage of apoptosis, the permeability of the cell membrane increases. At this time, propidium iodide (PI), as a nucleic acid dye, can enter the interior...

Embodiment 3

[0044] Example 3: Glibenclamide alleviates the proliferation inhibitory effect of irradiation on the vascular endothelial cell line HUVEC

[0045] 1. Experimental method:

[0046] The detection of cell proliferation ability adopts clone formation experiment. The principle is: a single cell will form a cell cluster of about 50 cells after more than 6 passages, which is called a clone. The number and size of clones can reflect the cell proliferation ability.

[0047] After the cells are irradiated, there are two forms of proliferative death and interphase death, so the clonogenic test can better reflect the proliferation ability of the cells. The specific operation steps are as follows: 24 hours before irradiation, plate the HUEVC cells, try to form a single cell, the cells will form colonies when they proliferate, and the staining points (blue) can be observed after staining. The more vigorous the cell proliferation, the more the number of staining points The more, the larger ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the technical field of medicines, and provides an application of glibenclamide or derivatives thereof in preparing medicines for preventing and protecting radiation-induced pulmonary injury. Furthermore, the invention also provides a pharmaceutical composition for preventing and protecting the radiation-induced pulmonary injury, wherein the pharmaceutical composition consists of the glibenclamide or derivatives thereof and pharmaceutically acceptable adjuvants. Based upon mice in-vivo experiments, the glibenclamide can obviously relieve a damage degree of blood vessel endothelium caused by radiation, so that increase in erythrocyte effusion is inhibited and the circumstance of pulmonary hemorrhage after the radiation is relieved; and through in-vivo cytological experiments, the glibenclamide can reduce an apoptosis rate of cells which accept the radiation and improve the circumstance of proliferation inhibition, showing that the glibenclamide, when applied in previous ways, can relieve the radiation-induced pulmonary injury of mice and reduce sensitivity of vascular endothelial cells to radiation; therefore, a new evidence is provided for prevention and protection of the radiation-induced pulmonary injury by virtue of the glibenclamide or derivatives thereof.

Description

technical field [0001] The invention belongs to the field of biomedicine, and specifically relates to the application of glibenclamide or its derivatives in the preparation of medicines for protecting radiation-induced lung injury, and a pharmaceutical composition containing glibenclamide or its derivatives. Background technique [0002] With the wide application of nuclear radiation in industrial, medical, military and other fields, the chances of radiation workers and the public being exposed have greatly increased, and radiation damage and protection have attracted more attention from the academic circles and the public. In emergencies such as nuclear wars and nuclear accidents, relevant personnel exposed to large doses of radiation may suffer from acute and chronic radiation sickness, among which radiation-induced lung injury (RILI) is difficult to prevent and treatment has received increasing attention. [0003] In addition, radiation-induced lung injury is also a comm...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/64A61P11/00
CPCA61K31/64
Inventor 蔡建明高福刘虎张沛李百龙杨彦勇杜继聪
Owner SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap